Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Here's What AstraZeneca's Recent FDA News Means for Shareholders
Here's What AstraZeneca's Recent FDA News Means for Shareholders
Here's What AstraZeneca's Recent FDA News Means for Shareholders
Submitted by
admin
on May 30, 2022 - 10:15am
Source:
Motley Fool
News Tags:
AstraZeneca
FDA
Imfinzi
tremelimumab
liver cancer
Headline:
Here's What AstraZeneca's Recent FDA News Means for Shareholders
snippet:
Tremelimumab and Imfinzi may have an addressable market in the tens of thousands of patients.
The potential drug pairing could top $1 billion in sales for AstraZeneca.
The stock seems like a good buy at this time for investors with a long-term mindset.
Do Not Allow Advertisers to Use My Personal information